Tuesday January 28, 2020 Change -1.15% Price $0.62
Your prediction: Prediction: Request




NBY Forecast and Technical Stock Analysis

Hold candidate since 2020-01-27 Loss -1.15% PDF

NovaBay Pharmaceuticals, Inc fell by -1.15% in the last day ( Tuesday, 28th Jan 2020 ) from $0.62 to $0.62 and has now fallen 3 days in a row. During the day the stock fluctuated 3.85% from a day low at $0.61 to a day high of $0.63. The price has risen in 6 of the last 10 days and is up by 2.73% over the past 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -156 708 shares and in total 107 755 shares bought and sold for approximately $66 398.60.

Quick summary:

  • 30 day high of the NBY stock price was $0.71 and low was $0.57.
  • 90 day high was $0.93 and low was $0.48.
  • 52 week high for NovaBay Pharmaceuticals, Inc - $4.04 and low - $0.23.
Top Trending Stocks


NovaBay Pharmaceuticals, Inc lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 4.28% during the next 3 months and, with 90% probability hold a price between $0.56 and $0.82 at the end of this period.

Top Golden Star Stocks


NovaBay Pharmaceuticals, Inc holds a sales signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $0.63. On a fall, the stock will find some support from the long-term average at approximately $0.61. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sales signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Friday January 24, 2020, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.

Access today's Top 20 Golden Star Companies

Relative Strength Index (RSI)

RSImin/max Values: [ 25 - 75 ]

RSI14 is 39 and the stock is currently not being overbought or oversold

* Stockinvest.us uses dynamical calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behaviour.

Support & Resistance

NovaBay Pharmaceuticals, Inc finds support from accumulated volume at $0.61.

Support: $0.61 Price: $0.62 Resistance: $0.62


In general the stock tends to have controlled movements, but the low liquidity has increased the risk substantially.

Our recommended stop-loss: $0.58 (-6.61%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from pivot top found 2 day(s) ago.)

8.10 %

Average volatility

Overall risk:

Very Low Low Medium High Very High

Hold/Accumulate Upgraded


NovaBay Pharmaceuticals, Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as hold candidate (hold or accumulate) in this position whilst awaiting further development.

Exchange: NASDAQ | NYSE | XLON | AMS | TSX | BRU

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 8.000 stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At